US equities |
MU $953.19 ▲+0.00% SNDK $1,482.33 ▲+0.00% ASML $1,717.76 ▲+0.00% SKHY $157.06 ▲+0.00% NVDA $228.52 ▲+0.00% INTC $102.81 ▲+0.00% SPCX $156.54 ▲+0.00% AMD $605.53 ▲+0.00%
FinancialContent

Upstream Bio, Inc. - Common Stock (NQ:UPB)

3.550 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Upstream Bio, Inc. - Common Stock

News headline image
ENAVATE's Zenas Bio Pharma add Is a Footnote — The Obexelimab Pipeline Is What to Watch ↗
This clinical-stage biotech develops immunology therapies for autoimmune and inflammatory diseases, with a diverse pipeline underway. 
Via The Motley Fool
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
Which stocks are experiencing notable movement on Wednesday? ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
Via Chartmill
News headline image
Why Did UPB Stock Pop 20% In Pre-Market Today? ↗
The company announced positive top-line results from its Phase 2 VALIANT trial evaluating Verekitug in adults with severe asthma. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
News headline image
Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗
The US market regular session of Tuesday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds ↗
Upstream Bio's Phase 2 trial of verekitug in chronic rhinosinusitis met all endpoints, showing reduced nasal polyps, congestion, and need for surgery. 
Via Benzinga
News headline image
Upstream Bio (UPB) Q2 R&D Soars 169% ↗
Via The Motley Fool
News headline image
Alerus Financial Posts Better-Than-Expected Earnings, Joins Celcuity, SES AI, Abercrombie & Fitch And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
Topics Artificial Intelligence
News headline image
Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency ↗
The company is progressing with multiple Phase 2 trials for its investigational treatment targeting severe respiratory diseases. 
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Amtech Systems, Tesla And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why ReShape Lifesciences Shares Are Trading Higher By Over 82%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise. 
Via MarketBeat
Topics Initial Public Offering
News headline image
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say ↗
Upstream Bio garners analyst optimism for its lead drug verekitug, which could disrupt the $7.5 billion asthma biologics market. 
Via Benzinga
News headline image
This Eaton Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Another Trio Of Biotech IPOs Made Friday Debut ↗
The Partners Group-backed KinderCare sold 24 million shares for $24 each this past Tuesday. Meanwhile, a new trio of biotech companies' shares came to market on Friday, as Upstream Bio, CeriBell, and... 
Via Talk Markets